World Health Organization logo World Health Organization

Tuberculosis

Fact Sheet No 104
Revised August 2002

Tuberculosis (TB) kills approximately 2 million people each year. The global epidemic is growing and becoming more dangerous. The breakdown in health services, the spread of HIV/AIDS and the emergence of multidrug-resistant TB are contributing to the worsening impact of this disease.

In 1993, the World Health Organization (WHO) took an unprecedented step and declared tuberculosis a global emergency, so great was the concern about the modern TB epidemic.

It is estimated that between 2002 and 2020, approximately 1000 million people will be newly infected, over 150 million people will get sick, and 36 million will die of TB - if control is not further strengthened.

Infection and Transmission

TB is a contagious disease. Like the common cold, it spreads through the air. Only people who are sick with pulmonary TB are infectious. When infectious people cough, sneeze, talk or spit, they propel TB germs, known as bacilli, into the air. A person needs only to inhale a small number of these to be infected.

Left untreated, each person with active TB will infect on average between 10 and 15 people every year. But people infected with TB will not necessarily get sick with the disease. The immune system 'walls off' the TB bacilli which, protected by a thick waxy coat, can lie dormant for years. When someone's immune system is weakened, the chances of getting sick are greater.

Global and Regional Incidence

Each year, more people are dying of TB. In Eastern Europe and Africa, TB deaths are increasing after almost 40 years of decline. In terms of numbers of cases, the biggest burden of TB is in south-east Asia.

Factors Contributing to the Rise in TB

HIV is accelerating the spread of TB

HIV and TB form a lethal combination, each speeding the other's progress. HIV weakens the immune system. Someone who is HIV-positive and infected with TB is many times more likely to become sick with TB than someone infected with TB who is HIV-negative. TB is a leading cause of death among people who are HIV-positive. It accounts for about 11% of AIDS deaths worldwide. In Africa, HIV is the single most important factor determining the increased incidence of TB in the past 10 years.

Poorly managed TB programmes are threatening to make TB incurable

Until 50 years ago, there were no drugs to cure TB. Now, strains that are resistant to a single drug have been documented in every country surveyed and, what is more, strains of TB resistant to all major anti-TB drugs have emerged. Drug-resistant TB is caused by inconsistent or partial treatment, when patients do not take all their drugs regularly for the required period because they start to feel better, doctors and health workers prescribe the wrong treatment regimens or the drug supply is unreliable. A particularly dangerous form of drug-resistant TB is multidrug-resistant TB (MDR-TB), which is defined as the disease due to TB bacilli resistant to at least isoniazid and rifampicin  the two most powerful anti-TB drugs. Rates of MDR-TB are high in some countries, especially in the former Soviet Union, and threaten TB control efforts.

From a public health perspective, poorly supervised or incomplete treatment of TB is worse than no treatment at all. When people fail to complete standard treatment regimens, or are given the wrong treatment regimen, they may remain infectious. The bacilli in their lungs may develop resistance to anti-TB drugs. People they infect will have the same drug-resistant strain. While drug-resistant TB is treatable, it requires extensive chemotherapy (up to two years of treatment) that is often prohibitively expensive (often more than 100 times more expensive than treatment of drug-susceptible TB), and is also more toxic to patients.

WHO and its international partners have formed the DOTS-Plus Working Group, which is attempting to determine the best possible strategy to manage MDR-TB. One of the goals of DOTS-Plus is to increase access to expensive second-line anti-TB drugs for WHO-approved TB control programmes in low- and middle-income countries.

Movement of people is helping the spread of TB

Global trade and the number of people travelling in aeroplanes have increased dramatically over the past 40 years. In many industrialized countries, at least one-half of TB cases are among foreign-born people. In the United States, nearly 40% of TB cases are among foreign-born people.

The number of refugees and displaced people in the world is also increasing. Untreated TB spreads quickly in crowded refugee camps and shelters. It is difficult to treat mobile populations, as treatment takes at least six months and should ideally be suvervised. As many as 50% of the world's refugees could be infected with TB. As they move, they may spread TB.

Effective TB Control

The WHO-recommended treatment strategy for detection and cure of TB is DOTS. DOTS combines five elements: political commitment, microscopy services, drug supplies, surveillance and monitoring systems and use of highly efficacious regimes with direct observation of treatment.

Once patients with infectious TB (bacilli visible in a sputum smear) have been identified using microscopy services, health and community workers and trained volunteers observe patients swallowing the full course of the correct dosage of anti-TB medicines (treatment lasts six to eight months). The most common anti-TB drugs are isoniazid, rifampicin, pyrazinamide, streptomycin and ethambutol.

Sputum smear testing is repeated after two months, to check progress, and again at the end of treatment. A recording and reporting system documents patients' progress throughout, and the final outcome of treatment.

Since DOTS was introduced on a global scale in 1991, about 10 million patients have received DOTS treatment. In half of China, cure rates among new cases are 96%. In Peru, widespread use of DOTS for more than five years has led to the successful treatment of 91 %of cases and a decline in incidence.

By the end of 2000, all 22 of the highest burden countries which bear 80% of the world's estimated incident cases had adopted DOTS. Fifty-five percent of the global population had access to DOTS, double the fraction reported in 1995. In the same year, 27% of estimated TB patients received treatment under DOTS, two and a half times the fraction reported in 1995.

WHO targets are to detect 70% of new infectious TB cases and to cure 85% of those detected. Ten countries had achieved these targets in 2000. Governments, nongovernmental organizations and civil society must continue to act to improve TB control if we are to reach these targets worldwide.

For more information contact:

Media Centre
Telephone: (+41 22) 791 2222
Email: mediaenquiries@who.int

CDS
Telephone: (+41) 22 791 4285
Email: cdsdoc@who.int

About WHO | Employment | Other UN Sites | Search | Site Map | Suggestions
© Copyright 2004 World Health Organization